143 related articles for article (PubMed ID: 37272088)
1. FOXM1 Contributes to Chemotherapy Sensitivity in Cervical Cancer by Regulating TTK.
Tang Q; Xu A; Yang Y; Zhang Y; Sun J
Discov Med; 2023 Jun; 35(176):208-220. PubMed ID: 37272088
[TBL] [Abstract][Full Text] [Related]
2. Pin1 modulates chemo-resistance by up-regulating FoxM1 and the involvements of Wnt/β-catenin signaling pathway in cervical cancer.
Wang T; Liu Z; Shi F; Wang J
Mol Cell Biochem; 2016 Feb; 413(1-2):179-87. PubMed ID: 26820938
[TBL] [Abstract][Full Text] [Related]
3. TTK is a potential therapeutic target for cisplatin-resistant ovarian cancer.
Liu Y; Zhu K; Guan X; Xie S; Wang Y; Tong Y; Guo L; Zheng H; Lu R
J Ovarian Res; 2021 Oct; 14(1):128. PubMed ID: 34598710
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of forkhead box protein M1 (FOXM1) in ovarian cancer correlates with poor patient survival and contributes to paclitaxel resistance.
Zhao F; Siu MK; Jiang L; Tam KF; Ngan HY; Le XF; Wong OG; Wong ES; Gomes AR; Bella L; Khongkow P; Lam EW; Cheung AN
PLoS One; 2014; 9(11):e113478. PubMed ID: 25411964
[TBL] [Abstract][Full Text] [Related]
5. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
[TBL] [Abstract][Full Text] [Related]
6. FOXM1 Promotes Drug Resistance in Cervical Cancer Cells by Regulating ABCC5 Gene Transcription.
Hou Y; Dong Z; Zhong W; Yin L; Li X; Kuerban G; Huang H
Biomed Res Int; 2022; 2022():3032590. PubMed ID: 35141332
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer.
Okada K; Fujiwara Y; Takahashi T; Nakamura Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Mori M; Doki Y
Ann Surg Oncol; 2013 Mar; 20(3):1035-43. PubMed ID: 23054116
[TBL] [Abstract][Full Text] [Related]
8. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
9. FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients.
Wang Y; Wen L; Zhao SH; Ai ZH; Guo JZ; Liu WC
Lung Cancer; 2013 Feb; 79(2):173-9. PubMed ID: 23177020
[TBL] [Abstract][Full Text] [Related]
10. Targeting FOXM1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer.
Westhoff GL; Chen Y; Teng NNH
Int J Gynecol Cancer; 2017 Oct; 27(8):1602-1609. PubMed ID: 28692634
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of the FoxM1 enhances the sensitivity of gastric cancer cells to cisplatin by targeting Mcl-1.
Li X; Liang J; Liu YX; Wang Y; Yang XH; Bao-Hongluan ; Zhang GL; Du J; Wu XH
Pharmazie; 2016 Jun; 71(6):345-8. PubMed ID: 27455555
[TBL] [Abstract][Full Text] [Related]
12. [Effects and molecular mechanisms of inhibiting FOXM1 expression on ovarian cancer cell line SKOV3 by Lentiviral vector].
Chen GQ; Yao ZW; Qi HB; Zhang H; Luo Y; Qin XF
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2012 Jan; 28(1):29-32. PubMed ID: 22230500
[TBL] [Abstract][Full Text] [Related]
13. FOXM1 modulates cisplatin sensitivity by regulating EXO1 in ovarian cancer.
Zhou J; Wang Y; Wang Y; Yin X; He Y; Chen L; Wang W; Liu T; Di W
PLoS One; 2014; 9(5):e96989. PubMed ID: 24824601
[TBL] [Abstract][Full Text] [Related]
14. Over-expression of FOXM1 transcription factor is associated with cervical cancer progression and pathogenesis.
Chan DW; Yu SY; Chiu PM; Yao KM; Liu VW; Cheung AN; Ngan HY
J Pathol; 2008 Jul; 215(3):245-52. PubMed ID: 18464245
[TBL] [Abstract][Full Text] [Related]
15. TTK (threonine tyrosine kinase) regulates the malignant behaviors of cancer cells and is regulated by microRNA-582-5p in ovarian cancer.
Lu N; Ren L
Bioengineered; 2021 Dec; 12(1):5759-5768. PubMed ID: 34516342
[TBL] [Abstract][Full Text] [Related]
16. TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR/autophagy pathway.
Qi G; Ma H; Li Y; Peng J; Chen J; Kong B
Cell Death Dis; 2021 Dec; 12(12):1135. PubMed ID: 34876569
[TBL] [Abstract][Full Text] [Related]
17. The novel circCLK3/miR-320a/FoxM1 axis promotes cervical cancer progression.
Hong H; Zhu H; Zhao S; Wang K; Zhang N; Tian Y; Li Y; Wang Y; Lv X; Wei T; Liu Y; Fan S; Liu Y; Li Y; Cai A; Jin S; Qin Q; Li H
Cell Death Dis; 2019 Dec; 10(12):950. PubMed ID: 31831728
[TBL] [Abstract][Full Text] [Related]
18. Domatinostat Targets the FOXM1-Survivin Axis to Reduce the Viability of Ovarian Cancer Cells Alone and in Combination with Chemotherapeutic Agents.
Nakagawa-Saito Y; Mitobe Y; Suzuki S; Togashi K; Sugai A; Kitanaka C; Okada M
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445993
[TBL] [Abstract][Full Text] [Related]
19. The suppression of FOXM1 and its targets in breast cancer xenograft tumors by siRNA.
Wang M; Gartel AL
Oncotarget; 2011 Dec; 2(12):1218-26. PubMed ID: 22203467
[TBL] [Abstract][Full Text] [Related]
20. ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance.
Millour J; de Olano N; Horimoto Y; Monteiro LJ; Langer JK; Aligue R; Hajji N; Lam EW
Mol Cancer Ther; 2011 Jun; 10(6):1046-58. PubMed ID: 21518729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
